Tirzepatide-associated interstitial kidney injury

by 3 months). This case highlights a rare, biopsy-proven adverse renal effect of tirzepatide and underscores the importance of considering interstitial nephritis in patients with unexplained kidney injury on incretin mimetic therapy. Although glucagon-like peptide-1 receptor agonists benefits outweigh rare risks of nephrotoxicity, regular monitoring of creatinine monitoring is advised.